Yeast strain for the production of proteins with modified O-glycosylation
View Patent ↗Lower eukaryotic host cells have been recombinantly engineered to produce glycoprotein having human-like O-glycosylation. The glycoproteins are useful for the production of glycoprotein compositions with advantages for the production of human therapeutics.
1. A method of producing a recombinant glycoprotein having O-Man-GlcNAc; O-Man-GlcNAc-Gal; or O-Man-GlcNAc-Gal-Sia as the predominant O-glycan thereof in Pichia pastoris host cell which comprises:
(a) providing Pichia pastoris host cells which
(i) do not express functional beta-mannosyltransferase enzymes Bmt 1, 2, 3 and 4, and phospho-mannose transferase enzymes Mnn4a, Mnn4b and Pno1; and
(ii) do express functional protein O-linked mannose β-1,2-N-linked acetylglucosaminyltransferase 1 (“POMGnT1”), UDP-GlcNAc transporter and α-1,2-mannosidase enzymes;
(b) transfecting or transforming the Pichia pastoris host cells with nucleic acid encoding the glycoprotein of interest; and
(c) culturing the Pichia pastoris host cells so that the recombinant glycoprotein is produced.
2. The method of claim 1 wherein the cells of step (a) further do not express Ktr1.
3. The method of claim 1 wherein the enzymes of step (a)(ii) further include one of the following combinations of enzymes:
(a) β1,4GalT, UDP-Gal transporter and UDP-Gal epimerase;
(b) β1,4GalT, UDP-Gal transporter, UDP-Gal epimerase; α2,6SialT; GNE; SPS; SPP; CSS; and CST; or
(c) β1,4GalT, UDP-Gal transporter, UDP-Gal epimerase; α2,3SialT; GNE; SPS; SPP; CSS; and CST.
4. The method of claim 1 wherein the UDP-GlcNAc transporter of step (a)(ii) is a Kluyveromyces lactis UDP-GlcNAc transporter, or a murine UDP-GlcNAc transporter.
5. The method of claim 1 wherein the α-1,2-mannosidase is derived from Trichoderma reesei, Saccharomyces sp., Coccidiodes sp., or Aspergillus sp.
6. The method of claim 1 wherein the POMGnT1 enzyme of step (a)(ii) comprises SEQ ID NO: 110, SEQ ID NO: 112 or SEQ ID NO: 118.
7. The method of claim 1 wherein the POMGnT1 enzyme from step (a)(ii) is derived from human, murine, or frog POMGnT1 sequences.
8. The method of claim 1 wherein nucleic acid encoding the POMGnT1 enzyme from step (a)(ii) is codon-optimized for expression in the lower eukaryotic host cell.
9. The method of claim 1 wherein the POMGnT1 of step (a)(ii) is encoded by nucleic acid sequence encoding POMGnT1 operatively linked to an ER and/or Golgi leader sequence which is that of or derived from a leader sequence of S. cerevisiae, Pichia pastoris , or Kluyveromyces lactis.
10. The method of claim 9 wherein the ER and/or Golgi leader sequence is derived from sequence of one of the following proteins: ScMNS1-s, ScMNN9-s, PpKre-2s; K1Gnt1-s, ScMNN2-s, ScMNN2-m, ScMNN5-s, ScMNN6-s, ScPMT5-m, PpPMT1-m or PpBET1-s.
11. The method of claim 9 wherein the nucleic acid sequence encoding POMGnT1 is operatively linked to a sequence selected from: SEQ ID NOs: 1-108.
12. The method of claim 9 wherein the nucleic acid sequence encoding POMGnT1 is operatively linked to a sequence selected from: SEQ ID NO 3 (or sequence encoding SEQ ID NO 4); SEQ ID NO 13 (or sequence encoding SEQ ID NO 14); SEQ ID NO 33 (or sequence encoding SEQ ID NO 34); SEQ ID NO 39 (or sequence encoding SEQ ID NO 40); SEQ ID NO 41 (or sequence encoding SEQ ID NO 42); SEQ ID NO 43 (or sequence encoding SEQ ID NO 44); SEQ ID NO 45 (or sequence encoding SEQ ID NO 46); SEQ ID NO 51 (or sequence encoding SEQ ID NO 52); SEQ ID NO 93 (or sequence encoding SEQ ID NO 94); SEQ ID NO 87 (or sequence encoding SEQ ID NO 88) or SEQ ID NO 105 (or sequence encoding SEQ ID NO 106).
13. The method of claim 9 wherein the nucleic acid sequence encoding POMGnT1 is operatively linked to an ER and/or Golgi leader sequence in one of the following combinations:
(a) human POMGnT1 sequence or catalytic domain sequence thereof operatively linked to a leader sequence which is that of, or derived from that of, a protein selected from: PpSEC12-s; ScMNN9-s; K1GNT1-s; ScMNN2-s; ScMNN2-m; ScPMT5-m; PpPMT1-m or PpBET1-s;
(b) human POMGnT1 sequence or catalytic domain sequence thereof operatively linked to a sequence selected from: SEQ ID NO 9 (or sequence encoding SEQ ID NO 10); SEQ ID NO 13 (or sequence encoding SEQ ID NO 14); SEQ ID NO 39 (or sequence encoding SEQ ID NO 40); SEQ ID NO 41 (or sequence encoding SEQ ID NO 42); SEQ ID NO 43 (or sequence encoding SEQ ID NO 44); SEQ ID NO 73 (or sequence encoding SEQ ID NO 74); SEQ ID NO 87 (or sequence encoding SEQ ID NO 88) or SEQ ID NO 105 (or sequence encoding SEQ ID NO 106);
(c) murine POMGnT1 sequence or catalytic domain sequence thereof operatively linked to a leader sequence which is that of, or derived from that of, a protein selected from: ScMNN9-s; PpKRE2-s; ScKTR2-s; K1GNT1-s; ScMNN2-s; ScMNN2-m; ScMNN5-s; ScMNN6-s; ScPMT5-m; ScPMT6-m; PpPMT1-s; PpPMT 2-s; PpPMT4-s; or PpBET1-s;
(d) murine POMGnT1 sequence or catalytic domain sequence thereof operatively linked to a sequence selected from: SEQ ID NO 13 (or sequence encoding SEQ ID NO 14); SEQ ID NO 33 (or sequence encoding SEQ ID NO 34); SEQ ID NO 37 (or sequence encoding SEQ ID NO 38); SEQ ID NO 39 (or sequence encoding SEQ ID NO 40); SEQ ID NO 41 (or sequence encoding SEQ ID NO 42); SEQ ID NO 43 (or sequence encoding SEQ ID NO 44); SEQ ID NO 45 (or sequence encoding SEQ ID NO 46); SEQ ID NO 51 (or sequence encoding SEQ ID NO 52); SEQ ID NO 73 (or sequence encoding SEQ ID NO: 74); SEQ ID NO 75 (or sequence encoding SEQ ID NO 76); SEQ ID NO 77 (or sequence encoding SEQ ID NO 78); SEQ ID NO 79 (or sequence encoding SEQ ID NO 80); SEQ ID NO 81 (or sequence encoding SEQ ID NO 82); or SEQ ID NO 105 (or sequence encoding SEQ ID NO 106);
(e) frog POMGnT1 sequence or catalytic domain sequence thereof operatively linked to a leader sequence which is that of, or derived from that of, a protein selected from: ScMNS1-s; ScSEC12-m; PpSEC12-s; ScMNN9-s; ScANP1-s; ScHOC1-s; ScMNN10-s; ScMNN11-s; PpKRE2-s; ScKTR2-s; K1GNT1-s; ScMNN2-s; ScMNN2-m; ScMNN1-s; ScMNN6-s; ScPMT5-m; PpPMT1-m; or PpBET1-s; or
(f) frog POMGnT1 sequence or catalytic domain sequence thereof operatively linked to a sequence selected from: SEQ ID NO 3 (or sequence encoding SEQ ID NO 4); SEQ ID NO 7 (or sequence encoding SEQ ID NO 8); SEQ ID NO 9 (or sequence encoding SEQ ID NO 10); SEQ ID NO 13 (or sequence encoding SEQ ID NO 14); SEQ ID NO 17 (or sequence encoding SEQ ID NO 18); SEQ ID NO 19 (or sequence encoding SEQ ID NO 20); SEQ ID NO 21 (or sequence encoding SEQ ID NO 22); SEQ ID NO 23 (or sequence encoding SEQ ID NO 24); SEQ ID NO 33 (or sequence encoding SEQ ID NO 34); SEQ ID NO 37 (or sequence encoding SEQ ID NO 38); SEQ ID NO 39 (or sequence encoding SEQ ID NO 40); SEQ ID NO 41 (or sequence encoding SEQ ID NO 42); SEQ ID NO 43 (or sequence encoding SEQ ID NO 44); SEQ ID NO 49 (or sequence encoding SEQ ID NO 50); SEQ ID NO 51 (or sequence encoding SEQ ID NO 52); SEQ ID NO 73 (or sequence encoding SEQ ID NO 74); SEQ ID NO 87 (or sequence encoding SEQ ID NO 88); or SEQ ID NO 105 (or sequence encoding SEQ ID NO 106).
14. The method of claim 1 wherein nucleic acid sequence encoding the POMGnT1 enzyme from step (a)(ii) is operatively linked to a Pichia AOX1, GAP, TEF or PMA promoter.
15. The method of claim 1 wherein nucleic acid sequence encoding the POMGnT1 enzyme from step (a)(ii) is operatively linked to a ScCYC1 transcription termination sequence.
16. The method of claim 1 wherein nucleic acid sequence encoding the POMGnT1 enzyme of step (a)(ii) is operatively linked to promoter and leader sequences; wherein the promoter, leader and POMGnT1 sequences utilized are one of the following promoter-leader-POMGnT1 combinations: AOX1-PpKRE2s-mouse POMGnT1; GAP-K1GNT1s-mouse POMGnT1; AOX1-K1GNT1s-mouse POMGnT1; GAP-K1GNT1s-frog POMGnT1; AOX1-ScMNN2s-mouse POMGnT1; GAP-ScMNN5s-mouse POMGnT1; AOX1-ScMNN5s-mouse POMGnT1; GAP-ScMNN6s-mouse POMGnT1; AOX1-ScPMT5m-mouse POMGnT1 or GAP-ScMNN6s-human POMGNT1.